Related Experiment Video
Updated: Jun 2, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Human immunodeficiency virus infection and left ventricular assist devices: a case series
Daniel B Sims1, Nir Uriel, José González-Costello
1Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA. das9093@nyp.org
Abstract:
Historically, advanced heart failure therapies were considered inappropriate for patients infected with human immunodeficiency virus (HIV). As HIV has become a chronic illness with the advent of highly active anti-retroviral therapy (HAART), cardiac transplantation has been used for selected HIV patients with end-stage heart failure. We present a case series describing the clinical outcomes with left ventricular assist device (LVAD) use in 4 patients with HIV. Three of the patients are alive: 1 after a successful bridge to transplant and the other 2 on continued device support at 18 and 13 months after implantation. No infectious complications occurred in 3 patients, and no opportunistic infections occurred in the fourth patient. De novo allosensitization did not occur in our patients after LVAD implantation. With the ongoing donor shortage, implantation of an LVAD in advanced heart failure patients with HIV with controlled viremia on HAART represents a viable option.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Endocarditis I: Introduction
